Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego



Status:Recruiting
Conditions:HIV / AIDS, Hepatitis, Hepatitis, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:6/16/2018
Start Date:January 1, 2018
End Date:December 31, 2020
Contact:Edward Cachay, MD, MAS
Email:ecachay@ucsd.edu
Phone:(619)543-3882

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego

A retrospective and prospective study among people living with HIV (PLWH) that assesses
hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals
(DAA) introduction, and its impact on the HCV epidemic among PLWH.

A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic
among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake
among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be
utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using
mathematical epidemic models, the study will assess levels of existing and scaled-up
interventions necessary for HCV elimination from PLWH in San Diego.

Inclusion Criteria:

- Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic

- With history of acute or chronic HCV infection defined as having a detectable HCV
viral load with or without a positive HCV antibody

Exclusion Criteria:

- With no history of or current HCV infection defined as having a negative HCV antibody
from 2008 to 2020
We found this trial at
1
site
Owen Clinic - University of California, San Diego
San Diego, California 92103
?
mi
from
San Diego, CA
Click here to add this to my saved trials